Ovid Therapeutics is a clinical-stage biotechnology company with a negligible and volatile revenue base, exemplified by a -88.3% year-over-year decline in 2026Q2 revenue to just $733K.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 13, 2026 | -$0.08+30.4% vs -$0.12 | $733,000+3320.6% vs $21,429 |
Q2 2026 May 12, 2026 | -$0.12+0.0% vs -$0.12 | — vs $56,667 |
Q2 2026 Mar 18, 2026 | $0.06+160.0% vs -$0.10 | $718,000+817.6% vs $78,250 |
Q4 2025 Nov 12, 2025 | -$0.17-13.3% vs -$0.15 | $132,000+110.9% vs $62,600 |
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced the appointment of Matt David, M.D., as Chief Financial Officer.
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today announced that the Company's management will participate in two upcoming investor conferences: Cantor Global Healthcare Conference – Wednesday, September 9 at 2:10 pm ET H.C.
BlackRock Inc. bought a new position in shares of Ovid Therapeutics (NASDAQ: OVID) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 10,823,480 shares of the company's stock, valued at approximately $29,115,000. BlackRock Inc. owned 5.80% of Ovid Therapeutics
Does Ovid Therapeutics (OVID) have what it takes to be a top stock pick for momentum investors? Let's find out.
Benchmark OVID against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Ovid Therapeutics Inc. (OVID)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.85 | $531.92M | -6.09 | 1181.27% | -2178.9% | -23.64% | — | |
| $21.23 | $3.64B | 10.28 | 11.87% | 30.13% | 28.03% | — | |
| $277.62 | $7.74B | -23.85 | -100% | — | -34.15% | — | |
| $306.20 | $6.14B | 118.77 | 60.4% | 20.27% | 5.22% | — | |
| $15.43 | $1.52B | -3.01 | 20.13% | -71.78% | — | — | |
| $65.44 | $5.43B | -51.55 | 114.51% | -9.17% | — | — |
Ovid Therapeutics Inc. (OVID) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Ovid Therapeutics Inc. (OVID) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 13, 2026·SEC
Jul 8, 2026·SEC
Jun 11, 2026·SEC
Get notified when OVID posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Ovid Therapeutics Inc. (OVID) stock FAQ — growth, dividends, profitability & financials explained
Ovid Therapeutics Inc. (OVID) reported $1.6M in revenue over the trailing twelve months. Revenue was $7.3M in fiscal year 2025.
Ovid Therapeutics Inc. (OVID) revenue fell by 76.2% over the trailing twelve months, compared with the twelve months before.
No. Ovid Therapeutics Inc. (OVID) reported a net loss of $34.5M over the trailing twelve months.
Ovid Therapeutics Inc. (OVID) had a return on equity (ROE) of -23.6% over the trailing twelve months. A negative ROE means the company lost money over the period.
Ovid Therapeutics Inc. (OVID) had negative free cash flow of $54.8M over the trailing twelve months.
